{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:17:41Z","timestamp":1791908261974,"version":"4.3.4"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.addr.2014.08.013","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T05:24:01Z","timestamp":1409549041000},"page":"24-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Inhaled antimicrobial therapy \u2013 Barriers to effective treatment"],"prefix":"10.1016","volume":"85","author":[{"given":"Jeffry","family":"Weers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2014.08.013_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE!: an update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 x \u201920 progress \u2013 development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/138161212799315975","article-title":"New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa","volume":"18","author":"Hofmann","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2014.08.013_bb0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/ppa.13.47","article-title":"Inhaled antibiotics to treat lung infection","volume":"2","author":"Cipolla","year":"2013","journal-title":"Pharm. Pat. Analyst"},{"key":"10.1016\/j.addr.2014.08.013_bb0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/eri.13.36","article-title":"Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia : an update","volume":"11","author":"Luyt","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.addr.2014.08.013_bb0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jinf.2013.08.010","article-title":"Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease","volume":"67","author":"Wilson","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.addr.2014.08.013_bb0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.08.013_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ppul.1950120306","article-title":"Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis","volume":"12","author":"Henry","year":"1992","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittant administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","article-title":"Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0065","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u04e7ring","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0070","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/jb.176.8.2137-2142.1994","article-title":"Biofilms, the customized microniche","volume":"176","author":"Costerton","year":"1994","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2014.08.013_bb0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/sj.clpt.6100247","article-title":"The challenge of treating biofilm-associated bacterial infections","volume":"82","author":"del Pozo","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.08.013_bb0080","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2217\/fmb.10.125","article-title":"Pseudomonas aeruginosa biofilms in cystic fibrosis","volume":"5","author":"H\u00f8iby","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.addr.2014.08.013_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb0090","first-page":"49","article-title":"Eradication of early Pseudomonas aeruginosa infection","volume":"4","author":"H\u00f8iby","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part 1: Physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2014.08.013_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clin. Pulm. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0105","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465813487412","article-title":"Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis","volume":"7","author":"Justo","year":"2013","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2007.0652","article-title":"Aerosolized antibiotics for non-cystic fibrosis bronchiectasis","volume":"21","author":"Rubin","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.08.013_bb0115","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0125","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.addr.2014.08.013_bb0135","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled dual release liposomal ciprofloxacin in non-cystic fibrosis (ORBIT-2): a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0150","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.08.013_bb0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.08.013_bb0170","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1164\/rccm.200210-1179OC","article-title":"Airway bacterial load and FEV decline in patients with chronic obstructive pulmonary disease","volume":"167","author":"Wilkinson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thorax.58.8.680","article-title":"Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis","volume":"58","author":"White","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0180","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1513\/pats.200701-003FM","article-title":"Exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"Anzueto","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.08.013_bb0185","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/archinte.165.8.891","article-title":"Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease","volume":"165","author":"Rosell","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0195","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1378\/chest.117.6.1638","article-title":"Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD","volume":"117","author":"Stockley","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0200","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMoa012561","article-title":"New strains of bacteria and exacerbations of chronic obstructive pulmonary disease","volume":"347","author":"Sethi","year":"2002","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0205","first-page":"1","article-title":"Pseudomonas aeruginosa in chronic obstructive pulmonary disease","author":"Murphy","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0210","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.117.5.1345","article-title":"Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD","volume":"117","author":"Adams","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00090311","article-title":"Moxifloxacin vs. amoxicillin\/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results","volume":"40","author":"Wilson","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.08.013_bb0220","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1378\/chest.127.6.2231","article-title":"Clinical significance of the infection-free interval in the management of acute bacterial exacerbations in chronic bronchitis","volume":"127","author":"Chodosh","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0225","first-page":"A3037","article-title":"A phase 2 study to evaluate the safety, tolerability, and efficacy of levofloxacin inhalation solution (MP-376) administered for 5days every 28days to prevent acute exacerbations in high risk COPD patients","volume":"185","author":"Sethi","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.08.013_bb0230","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/653060","article-title":"Mortality, attributable mortality, and clinical events and endpoints for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia","volume":"51","author":"Muscedere","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0235","first-page":"416","article-title":"Should aerosolized antibiotics be administered to prevent or treat ventilator-associated pneumonia in patients who do not have cystic fibrosis?","volume":"52","author":"MacIntyre","year":"2007","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0240","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"Overview of nosocomial infections caused by gram-negative bacilli","volume":"41","author":"Gaynes","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0245","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1378\/chest.122.6.2115","article-title":"Epidemiology and outcomes of ventilator-associated pneumonia in a large U.S. database","volume":"122","author":"Rello","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0250","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1186\/cc8206","article-title":"Pharmacokinetics and lung delivery of PDDS-aeroslized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia","volume":"13","author":"Luyt","year":"2009","journal-title":"Crit. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0255","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00134-011-2420-0","article-title":"BAY41-6551 achieves bactericidal tracheal aspirate concentrations in mechanically ventilated patients with Gram-negative pneumonia","volume":"38","author":"Niederman","year":"2012","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0260","doi-asserted-by":"crossref","DOI":"10.1089\/jamp.2013.1100","article-title":"A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered with the PARI Investigational eFlow Inline Nebulizer System in mechanically ventilated patients","author":"Montgomery","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0265","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1592\/phco.29.9.1054","article-title":"Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia","volume":"29","author":"Czosnowski","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.addr.2014.08.013_bb0270","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/CCM.0b013e31817c0f9e","article-title":"Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit","volume":"36","author":"Palmer","year":"2008","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0275","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","article-title":"Efficacy of high-dose nebulized colisitin in ventilator-associated pneumonia caused by multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"117","author":"Lu","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.addr.2014.08.013_bb0280","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4187\/respcare.01556","article-title":"Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia","volume":"57","author":"Arnold","year":"2012","journal-title":"Respir. Care"},{"issue":"S1","key":"10.1016\/j.addr.2014.08.013_bb0285","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1086\/653051","article-title":"Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box","volume":"51","author":"Craven","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0290","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s12325-011-0051-z","article-title":"Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update","volume":"28","author":"Abu-Salah","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2014.08.013_bb0295","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QCO.0b013e3283229fdb","article-title":"Nosocomial tracheobronchitis","volume":"22","author":"Nseir","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0300","series-title":"Inhaled drug therapy for treatment of tuberculosis","first-page":"71","volume":"91","author":"Misra","year":"2011"},{"key":"10.1016\/j.addr.2014.08.013_bb0305","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/jps.23705","article-title":"Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis","volume":"102","author":"Hickey","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.08.013_bb0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.08.013_bb0320","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice","volume":"41","author":"Conley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0325","first-page":"63","volume":"1","author":"Talton","year":"2010","journal-title":"Proc. Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0330","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0335","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/jac\/dkr567","article-title":"Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis","volume":"67","author":"Kirkpatrick","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0340","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/655956","article-title":"Development of new antibacterials: a laudable aim, but what is the value?","volume":"51","author":"Tillotson","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0345","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1473-3099(13)70318-9","article-title":"Antibiotic resistance \u2013 the need for global solutions","volume":"13","author":"Laxminarayan","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.addr.2014.08.013_bb0350","first-page":"11","article-title":"Cystic fibrosis drug developers: victims of our own success","volume":"2008","author":"VanDevanter","year":"2008","journal-title":"Proc. Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0355","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy, and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0360","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0365","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sdium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomized study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"issue":"Suppl. 34","key":"10.1016\/j.addr.2014.08.013_bb0370","first-page":"235","article-title":"Randomised, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis \u2013 a Phase IIb study of ciprofloxacin dry powder for inhalation","volume":"46","author":"Dorkin","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0375","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1513\/pats.200611-180HT","article-title":"Monitoring cystic fibrosis lung disease in clinical trials: is it time for a change?","volume":"4","author":"Tiddens","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.08.013_bb0380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1513\/pats.200703-042BR","article-title":"Mucociliary clearance as an outcome measure for cystic fibrosis clinical research","volume":"4","author":"Donaldson","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2014.08.013_bb0385","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/thx.2007.082628","article-title":"Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis","volume":"63","author":"Horsley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0390","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000347120","article-title":"Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone \/formoterol","volume":"86","author":"Vos","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.addr.2014.08.013_bb0395","series-title":"The win-ratio method, a novel hierarchical endpoint for pneumonia trials in patients on mechanical ventilation","author":"Montgomery","year":"2014"},{"key":"10.1016\/j.addr.2014.08.013_bb0400","first-page":"37","article-title":"Aerosol antibiotics in cystic fibrosis: yesterday, today, and tomorrow","volume":"1","author":"Geller","year":"2008","journal-title":"Proc. Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0405","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1164\/ajrccm.156.5.9604093","article-title":"RhDNase I aerosol deposition and related factors in cystic fibrosis","volume":"156","author":"Diot","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0410","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/17425247.2014.873402","article-title":"Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery","volume":"11","author":"Newman","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0415","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.rmed.2007.11.003","article-title":"Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD","volume":"102","author":"Lavorini","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0420","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/089426803769017613","article-title":"Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care","volume":"16","author":"Molimard","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0425","first-page":"117","article-title":"Appealing to users \u2013 designing inhalers to maximize compliance and minimize misuse","volume":"1","author":"Dixon","year":"2009","journal-title":"Proc. Respir. Drug Deliv. Eur."},{"key":"10.1016\/j.addr.2014.08.013_bb0430","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.prrv.2006.04.168","article-title":"Aerosol therapy: regimen and device compliance in daily practice","volume":"7S","author":"Everard","year":"2006","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.addr.2014.08.013_bb0435","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry powder formulation of tobramycin using PulmoSphere\u2122 technology","volume":"4","author":"Geller","year":"2011","journal-title":"J. Aerosol Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0440","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0445","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2466-11-5","article-title":"Adherence with tobramycin inhaled solution and health care utilization","volume":"11","author":"Briesacher","year":"2011","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0450","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jcf.2012.12.012","article-title":"Adherence to nebulized therapies in adolescents with cystic fibrosis is best on week-days during school term time","volume":"12","author":"Ball","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0455","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/ppul.20860","article-title":"The science of aerosol delivery in cystic fibrosis","volume":"43","author":"Geller","year":"2008","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0460","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MCP.0b013e328330d974","article-title":"Infection control in cystic fibrosis: barriers to implementation","volume":"1","author":"Saiman","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0465","first-page":"1504","article-title":"Nebulizer use and maintenance by cystic fibrosis patients: a survey study","volume":"49","author":"Lester","year":"2004","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0470","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2214.2006.00669.x","article-title":"Microbial contamination of nebulizers in the home treatment of cystic fibrosis","author":"Blau","year":"2007","journal-title":"Child Care Health Dev."},{"key":"10.1016\/j.addr.2014.08.013_bb0475","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4187\/002013209790983250","article-title":"New aerosol delivery devices for cystic fibrosis","volume":"54","author":"Kesser","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0480","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jamp.2007.0663","article-title":"Aerosol delivery during mechanical ventilation: from basic techniques to new devices","volume":"21","author":"Dhand","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0485","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1517\/17425247.3.5.693","article-title":"New advances in aerosolized drug delivery: vibrating membrane nebulizer technology","volume":"3","author":"Lass","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0490","first-page":"1406","article-title":"Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol","volume":"47","author":"Dhand","year":"2002","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2014.08.013_bb0495","first-page":"338s","article-title":"Reduction in nebulisation time of aqueous drug solutions by the eFlow\u00ae rapid in comparison to a jet nebulizer to improve patient convenience and compliance","volume":"26","author":"Keller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.08.013_bb0500","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0505","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/jamp.2008.0712","article-title":"Changes in performance of the PARI eFlow\u00ae rapid and PARI LC Plus during 6months use by CF patients","volume":"22","author":"Rottier","year":"2009","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0510","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/jamp.2009.Cor1","article-title":"Performance of PARI e-Flow (Letters to the Editor)","volume":"23","author":"Perkins","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0515","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/17425247.1.1.165","article-title":"Adaptive aerosol delivery (AAD) technology","volume":"1","author":"Denyer","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0520","first-page":"206","article-title":"Mode of breathing \u2013 tidal or slow and deep \u2013 through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA","volume":"17","author":"Nikander","year":"2006","journal-title":"Proc. Drug Deliv. Lungs"},{"key":"10.1016\/j.addr.2014.08.013_bb0525","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2009.04.006","article-title":"Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis","volume":"8","author":"McNamara","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0530","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/17425247.2.4.763","article-title":"Controlled inhalation of aerosolized therapeutics","volume":"2","author":"Bennett","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0535","first-page":"509","article-title":"Inhaled drug delivery in cystic fibrosis is improved by controlled breathing pattern","volume":"2","author":"Scheuch","year":"2005","journal-title":"Proc. Respir. Drug Deliv. Eur. IX"},{"issue":"1","key":"10.1016\/j.addr.2014.08.013_bb0540","first-page":"55","article-title":"Device engineering insights into TOBI\u00ae Podhaler\u2122: a development case study of high efficiency powder delivery to cystic fibrosis patients","volume":"2011","author":"Maltz","year":"2011","journal-title":"Proc. Respir. Drug Deliv. Eur."},{"issue":"Suppl. 36","key":"10.1016\/j.addr.2014.08.013_bb0545","first-page":"352","article-title":"In vitro aerosol delivery performance of tobramycin inhalation powder for inhalation (TOBI\u00ae Podhaler\u2122) using inspiratory flow profiles from cystic fibrosis patients","volume":"48","author":"Haynes","year":"2013","journal-title":"Pediatr. Pulmonol."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb0550","first-page":"R6156","article-title":"A novel high payload dry powder formulation of ciprofloxacin for management of chronic lung infections","volume":"13","author":"Gupta","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2014.08.013_bb0555","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.addr.2014.08.013_bb0560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2013.10.019","article-title":"Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation","volume":"86","author":"Hoppentocht","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2014.08.013_bb0565","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/089426803321919898","article-title":"Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction","volume":"16","author":"Broeders","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0570","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0954-6111(97)90009-3","article-title":"Flow early in the inspiratory maneuvre affects the aerosol particle size distribution from a Turbuhaler","volume":"91","author":"Everard","year":"1997","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0575","first-page":"284","article-title":"Young cystic fibrosis patients can effectively use a novel high-payload capsule-based dry powder inhaler with tobramycin powder for inhalation (TPI)","volume":"27","author":"Standaert","year":"2004","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0580","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1023\/A:1015322616613","article-title":"Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere\u00ae powder","volume":"19","author":"Duddu","year":"2002","journal-title":"Pharm. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb0585","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/jamp.2010.0838","article-title":"Pulmonary formulations: what remains to be done?","volume":"23","author":"Weers","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0590","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphere platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0595","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/jamp.2012.0973","article-title":"Dose emission characteristics of placebo PulmoSphere particles are unaffected by a subject\u2019s inhalation maneuver","volume":"26","author":"Weers","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0600","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jamp.2013.1080","article-title":"Overcoming dose limitations using the Orbital multi-breath dry powder inhaler","volume":"27","author":"Young","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0605","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1517\/17425247.2010.538379","article-title":"Single-use disposable dry powder inhalers for pulmonary drug delivery","volume":"7","author":"Friebel","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0610","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2005.11.013","article-title":"Testing and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer\u00ae) for higher powder doses","volume":"28","author":"de Boer","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.08.013_bb0615","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0620","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0625","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulized Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb0630","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1185\/03007995.2013.805122","article-title":"Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial","volume":"29","author":"Galeva","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.addr.2014.08.013_bb0635","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0640","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0645","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/cs0700301","article-title":"Chemical specificity of coughing in man","volume":"70","author":"Godden","year":"1986","journal-title":"Clin. Sci."},{"key":"10.1016\/j.addr.2014.08.013_bb0650","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/cs0740373","article-title":"Effects of pH and osmolarity on aerosol-induced cough in normal volunteers","volume":"74","author":"Lowry","year":"1988","journal-title":"Clin. Sci."},{"key":"10.1016\/j.addr.2014.08.013_bb0655","first-page":"211","article-title":"Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone","volume":"129","author":"Eschenbacher","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0660","series-title":"TOBI technical monograph","year":"1998"},{"key":"10.1016\/j.addr.2014.08.013_bb0665","unstructured":"A.B. Montgomery, Aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis, U.S. Patent 8,636,983, 2014."},{"key":"10.1016\/j.addr.2014.08.013_bb0670","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.07-2294","article-title":"Inhaled mannitol improves lung function in cystic fibrosis","volume":"133","author":"Jaques","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.addr.2014.08.013_bb0675","doi-asserted-by":"crossref","first-page":"A619","DOI":"10.1016\/j.jval.2013.08.1805","article-title":"Efficacy of inhaled antibiotics in CF patients with chronic P. aeruginosa infection: a network meta-analysis","volume":"16","author":"Janssen","year":"2013","journal-title":"Value Health"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.08.013_bb0680","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(13)60216-7","article-title":"Improved tolerability, adherence, and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulized antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS)","volume":"12","author":"Harrison","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0685","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/17512433.2.2.119","article-title":"Antibiotic resistance: the challenge from an industry perspective","volume":"2","author":"Tillotson","year":"2009","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2014.08.013_bb0690","first-page":"445","article-title":"Chemo-therapeutics: scientific principles, methods, and results","author":"Ehrlich","year":"1913","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2014.08.013_bb0695","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.43.7.1756","article-title":"Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacteriu, bovis BCG and Staphylococcus aureus","volume":"43","author":"Dong","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 3","key":"10.1016\/j.addr.2014.08.013_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The role of PK\/PD parameters to avoid selection and increase of resistance: mutant prevention concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0705","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17476348.1.1.7","article-title":"MICs, MPCs and PK\/PDs: a match (sometimes) made in hosts","volume":"1","author":"Hesje","year":"2007","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0710","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.76.6.505","article-title":"Specific polysaccharide content of pneumoni lungs","volume":"76","author":"Firsch","year":"1942","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0715","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.47.1.440-441.2003","article-title":"Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae","volume":"47","author":"Hansen","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0720","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/jac\/dkg255","article-title":"Stretching the mutant prevention concentration (MPC) beyond its limits","volume":"51","author":"Smith","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0725","series-title":"Internal report from JMI Laboratories","author":"Sader","year":"2004"},{"key":"10.1016\/j.addr.2014.08.013_bb0730","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.39.1.264","article-title":"Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily verus twice daily","volume":"39","author":"Santre","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0735","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/ajrccm.163.6.2007020","article-title":"Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia","volume":"163","author":"Dennesen","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0740","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00003246-200106000-00003","article-title":"Experience with a clinical guideline for the treatment of ventilator-associated pneumonia","volume":"29","author":"Ibrahim","year":"2001","journal-title":"Crit. Care Med."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb0745","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/504484","article-title":"Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit?","volume":"43","author":"Kollef","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0750","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000004","article-title":"Aerosolized antibiotics: do they add to the treatment of pneumonia?","volume":"26","author":"Kollef","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb0755","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1086\/504486","article-title":"Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species","volume":"43","author":"Rahal","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0760","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended spectrum \u03b2-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2014.08.013_bb0765","first-page":"A3236","article-title":"Synergistic effects for a combination of amikacin and fosfomycin against selected Gram-negative pathogens","volume":"187","author":"Montgomery","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0770","first-page":"263","article-title":"Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum","volume":"38","author":"Mendelman","year":"2012","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0775","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/clinids\/3.1.28","article-title":"Postantibiotic suppression of bacterial growth","volume":"3","author":"Bundtzen","year":"1981","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0780","first-page":"153","article-title":"The postantibiotic effect: a review of in vitro and in vivo data","volume":"25","author":"Zhanel","year":"1991","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.addr.2014.08.013_bb0785","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ppul.1950070413","article-title":"Safety of aerosol tobramycin for 3months to patients with cystic fibrosis","volume":"7","author":"Smith","year":"1989","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0790","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0795","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S1569-1993(02)00002-4","article-title":"Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?","volume":"1","author":"Smith","year":"2002","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb0800","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/14656566.2010.482102","article-title":"Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine","volume":"11","author":"Elborn","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.addr.2014.08.013_bb0805","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1164\/ajrccm.156.4.ed-14","article-title":"Is \u201ccrop rotation\u201d of antibiotics the solution to a \u201cresistant\u201d problem in the ICU?","volume":"156","author":"Niederman","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0815","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/514620","article-title":"The pharmacodynamics of aminoglycosides","volume":"27","author":"Lacy","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2014.08.013_bb0820","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1989.4","article-title":"Once-daily dosing decreases renal accumulation of gentamicin and netilmicin","volume":"45","author":"Verpooten","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2014.08.013_bb0830","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/AAC.45.4.999-1007.2001","article-title":"Riddle of biofilm resistance","volume":"45","author":"Lewis","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0835","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1183\/09031936.00042012","article-title":"Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"40","author":"Hurley","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2014.08.013_bb0840","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1462-2920.2006.001001.x","article-title":"The galactophilic lectin, LecA contributes to biofilm development in Pseudomonas aeruginosa","volume":"8","author":"Diggle","year":"2006","journal-title":"Environ. Microbiol."},{"key":"10.1016\/j.addr.2014.08.013_bb0845","doi-asserted-by":"crossref","first-page":"10631","DOI":"10.1002\/anie.201104342","article-title":"A glycopeptide dendrimer inhibitor of the galactose-specific lectin LecA and of Pseudompnas aeruginosa biofilms","volume":"50","author":"Kadam","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2014.08.013_bb0850","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.chembiol.2008.10.009","article-title":"Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB","volume":"15","author":"Johansson","year":"2008","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2014.08.013_bb0855","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2008-0299OC","article-title":"Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells","volume":"41","author":"Moreau-Marquid","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2014.08.013_bb0860","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI30783","article-title":"The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity","volume":"117","author":"Kaneko","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2014.08.013_bb0865","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jac\/dkn422","article-title":"Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa","volume":"62","author":"Halwani","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0870","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tim.2008.11.002","article-title":"Preventing biofilms of clinically relevant organisms using bacteriophages","volume":"17","author":"Donlan","year":"2009","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2014.08.013_bb0875","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jamp.2012.1001","article-title":"Respirable bacteriophages for the treatment of bacterial lung infections","volume":"26","author":"Hoe","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0880","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1002\/jps.22715","article-title":"Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections","volume":"100","author":"Matinkoo","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2014.08.013_bb0885","unstructured":"N.S. Faithfull, J.G. Weers, Partial liquid breathing of fluorocarbons, U.S. Patent 5,490,498 (1996)."},{"key":"10.1016\/j.addr.2014.08.013_bb0890","unstructured":"B. Fuhrman, Perfluorocarbon associated gas exchange, U.S. Patent 5,437,272 (1995)."},{"key":"10.1016\/j.addr.2014.08.013_bb0895","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00000658-199811000-00009","article-title":"Partial liquid ventilation in adult patients with ARDS: a multicenter Phase I-II trial","volume":"228","author":"Hirschl","year":"1996","journal-title":"Ann. Surg."},{"key":"10.1016\/j.addr.2014.08.013_bb0900","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00003246-199601000-00006","article-title":"Initial experience with partial liquid ventilation in pediatric patients with acute respiratory distress syndrome","volume":"24","author":"Gauger","year":"1996","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0905","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-1139(00)80064-0","article-title":"A physicochemical evaluation of perfluorochemicals for oxygen transport applications","volume":"64","author":"Weers","year":"1993","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.addr.2014.08.013_bb0910","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/17476348.2.2.273","article-title":"Anti-inflammatory effects of perfluorocarbon compounds","volume":"2","author":"Lehmler","year":"2008","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0915","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0954-6111(99)90261-5","article-title":"Intratracheal delivery strategy of gentamicin with partial liquid ventilation","volume":"93","author":"Cullen","year":"1999","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0920","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ppul.1100","article-title":"Intratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs","volume":"32","author":"Cox","year":"2001","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0925","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1023\/A:1013078330485","article-title":"Liquid dose pulmonary instillation of gentamicin PulmoSpheres formulations: tissue distribution and pharmacokinetics in rabbits","volume":"18","author":"Smith","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2014.08.013_bb0930","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00003246-200202000-00021","article-title":"Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia","volume":"30","author":"Dickson","year":"2002","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0935","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1553-2712.2003.tb00567.x","article-title":"Prevention of descending pneumonia in rats with perflubron-delivered tobramycin","volume":"10","author":"Dickson","year":"2003","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb0940","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkf226","article-title":"Combined bactericidal activity of perfluorooctyl bromide and aminoglycosides against Pseudomonas aeruginosa","volume":"50","author":"Jung","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0945","first-page":"91","article-title":"Homodispersion technology for HFA suspensions: particle engineering to reduce dosing variance","volume":"1","author":"Weers","year":"2000","journal-title":"Proc. Respir. Drug Deliv. Eur. VII"},{"key":"10.1016\/j.addr.2014.08.013_bb0950","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.22989","article-title":"Long-term efficacy and safety of aerosolized tobramycin 300mg\/4ml in cystic fibrosis","author":"Mazurek","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0955","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2014.08.013_bb0960","doi-asserted-by":"crossref","first-page":"P81","DOI":"10.1186\/cc12019","article-title":"In vitro efficiency of the Amikacin Inhale system, a novel integrated drug-device delivery system","volume":"17","author":"Kadrichu","year":"2013","journal-title":"Crit. Care"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2014.08.013_bb0965","first-page":"21","article-title":"A formulation of aerosolized tobramycin (Bramitob\u00ae) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"9","author":"Chuchalin","year":"2009","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.addr.2014.08.013_bb0970","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace\u2122) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb0975","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/14656566.2010.482102","article-title":"Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine","volume":"11","author":"Elborn","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.addr.2014.08.013_bb0985","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1128\/AAC.01744-10","article-title":"Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects","volume":"55","author":"Geller","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb0990","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0378-5173(92)90244-V","article-title":"Physicochemical properties of the fluoroquinolone antimicrobials III. Complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility","volume":"87","author":"Ross","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2014.08.013_bb0995","unstructured":"http:\/\/clinicaltrials.gov\/show\/NCT01746095, accessed 4\/15\/2014."},{"key":"10.1016\/j.addr.2014.08.013_bb1000","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2010.08.019","article-title":"Lung deposition of inhaled tobramycin with eFlow Rapid\/LC Plus jet nebulizer in healthy and cystic fibrosis subjects","volume":"10","author":"Lenney","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb1005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2014.08.013_bb1010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.39.1.264","article-title":"Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily","volume":"39","author":"Santr\u00e9","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2014.08.013_bb1015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00063198-200311000-00008","article-title":"Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management","volume":"9","author":"Rosenfeld","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"1","key":"10.1016\/j.addr.2014.08.013_bb1020","first-page":"1","article-title":"The microbiome and airway disease: role in pathogenesis, presentation, and response to treatment","volume":"2014","author":"Boushey","year":"2014","journal-title":"Proc. Respir. Drug Deliv."},{"key":"10.1016\/j.addr.2014.08.013_bb1025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/thoraxjnl-2011-201183","article-title":"Significance of the microbiome in obstructive lung disease","volume":"67","author":"Han","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.addr.2014.08.013_bb1030","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/ers.11.76","article-title":"The emrging relationship between the airway microbiota and chronic respiratory disease: clinical implications","volume":"5","author":"Huang","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.addr.2014.08.013_bb1035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1046\/j.1365-2958.2003.03803.x","article-title":"Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication","volume":"50","author":"Duan","year":"2003","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.addr.2014.08.013_bb1040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/omi.2009.0100","article-title":"A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations","volume":"14","author":"Huang","year":"2010","journal-title":"OMICS"},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2014.08.013_bb1045","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1569-1993(14)60048-5","article-title":"Once daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa","volume":"13","author":"Bilton","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.addr.2014.08.013_bb1050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/jamp.2011.0911","article-title":"Regulatory aspects of Phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections","volume":"25","author":"Montgomery","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X14001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T19:18:00Z","timestamp":1598210280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X14001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":204,"alternative-id":["S0169409X14001872"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2014.08.013","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled antimicrobial therapy \u2013 Barriers to effective treatment","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2014.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}